US 2026/0308250 A1 · ANTI-HUMAN INTERLEUKIN 23 MONOCLONAL ANTIBODY AND APPLICATION THEREOF

Abstract

The present invention relates to an anti-human interleukin 23 (hIL-23) monoclonal antibody and an application thereof. The anti-human interleukin 23 (hIL-23) monoclonal antibody comprises three heavy chain complementary determining regions (CDR-H1, CDR-H2 and CDR-H3) and three light chain complementary determining regions (CDR-L1, CDR-L2 and CDR-L3), wherein (a): the amino acid sequence of the CDR-H1 is as shown in SEQ ID NO: 1, (b): the amino acid sequence of the CDR-H2 is as shown in SEQ ID NO: 2, (c): the amino acid sequence of the CDR-H3 is as shown in SEQ ID NO: 3, (d): the amino acid sequence of the CDR-L1 is as shown in SEQ ID NO: 4, (e): the amino acid sequence of the CDR-L2 is as shown in SEQ ID NO: 5, and (f): the amino acid sequence of the CDR-L3 is as shown in SEQ ID NO: 6. Compared with existing anti-human interleukin 23 monoclonal antibodies (Guselkumab and Risankizumab), the hIL-23 binding affinity of the anti-human interleukin 23 (hIL-23) monoclonal antibody is equivalent, but the antagonistic activity at the cellular level is superior to Guselkumab, and equivalent to Risankizumab.

Claims28

Dependent claims

A method for treating a disease related to interleukin 23 (IL-23) mediated signal transduction in a subject in need thereof, the method comprising

administering to the subject an isolated anti-human IL-23 antibody comprising a heavy chain variable region comprising three heavy chain complementary determining regions (CDR-H1, CDR-H2 and CDR-H3) and a light chain variable region comprising three light chain complementary determining regions (CDR-L1, CDR-L2 and CDR-L3), wherein:
(a) the amino acid sequence of CDR-H1 is represented by SEQ ID NO:
1;
(b) the amino acid sequence of CDR-H2 is represented by SEQ ID NO:
2;
(c) the amino acid sequence of CDR-H3 is represented by SEQ ID NO:
3;
(d) the amino acid sequence of CDR-L1 is represented by SEQ ID NO:
4;
(e) the amino acid sequence of CDR-L2 is represented by SEQ ID NO:
5;
and
(f) the amino acid sequence of CDR-L3 is represented by SEQ ID NO:
6.

11 more elements

A method for treating a disease related to interleukin 23 (IL-23) mediated signal transduction in a subject in need thereof, the method comprising

administering to the subject a pharmaceutical composition comprising an isolated anti-human IL-23 antibody comprising a heavy chain variable region comprising three heavy chain complementary determining regions (CDR-H1, CDR-H2 and CDR-H3) and a light chain variable region comprising three light chain complementary determining regions (CDR-L1, CDR-L2 and CDR-L3), wherein:
(a) the amino acid sequence of CDR-H1 is represented by SEQ ID NO:
1;
(b) the amino acid sequence of CDR-H2 is represented by SEQ ID NO:
2;
(c) the amino acid sequence of CDR-H3 is represented by SEQ ID NO:
3;
(d) the amino acid sequence of CDR-L1 is represented by SEQ ID NO:
4;
(e) the amino acid sequence of CDR-L2 is represented by SEQ ID NO:
5;
and
(f) the amino acid sequence of CDR-L3 is represented by SEQ ID NO:
6.

11 more elements

Dependencies are inferred from the claim text.

Anti-human interleukin 23 monoclonal antibody and application thereof

Life of this patent

Anti-human interleukin 23 monoclonal antibody and application thereof

Life of this patent

Abstract

Claims28